Vir Biotechnology Inc. (VIR) is a clinical-stage immunology-based biotechnology company that develops treatments for infectious diseases. The company's lead product candidate, VIR-7831, is a monoclonal antibody that targets the spike protein of the SARS-CoV-2 virus, which causes COVID-19. VIR-7831 is being evaluated in clinical trials for the treatment and prevention of COVID-19. Vir Biotechnology is also developing other product candidates targeting various infectious diseases, including hepatitis B virus, influenza A virus, and human immunodeficiency virus (HIV). The company is headquartered in San Francisco, California, and as of September 2021, had a market capitalization of approximately $7.3 billion.
Vir Biotechnology Inc. (VIR) is a clinical-stage immunology-based biotechnology company that develops treatments for infectious diseases. The company's lead product candidate, VIR-7831, is a monoclonal antibody that targets the spike protein of the SARS-CoV-2 virus, which causes COVID-19. VIR-7831 is being evaluated in clinical trials for the treatment and prevention of COVID-19. Vir Biotechnology is also developing other product candidates targeting various infectious diseases, including hepatitis B virus, influenza A virus, and human immunodeficiency virus (HIV). The company is headquartered in San Francisco, California, and as of September 2021, had a market capitalization of approximately $7.3 billion.